CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Induction Chemotherapy followed by Response Adapted Chemoradiationradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01716195
NCT01716195Phase 2Completed

Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV)

University of California, Davis·interventional·Posted Oct 29, 2012·Updated Feb 26, 2021

In Brief

A Phase 2 clinical trial evaluating Induction Chemotherapy followed by Response Adapted Chemoradiation for Head and Neck Cancer. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 29, 2012
Enrollment StartOct 1, 2012
Primary CompletionMar 8, 2017
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.7 years ago

Interventions

Induction Chemotherapy followed by Response Adapted Chemoradiationradiation

All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.